非小细胞肺癌的治疗方案选择.pptVIP

Reference 2: P4622 * Reference 3: P477 * Reference 4: P1872 Reference 5: P2926 Reference 6: P1-2 * Reference 7: P3856 Reference 8: P847 Reference 9: P348 * Reference 7: P3852 Reference 8: P847 * JMDB研究是是迄今样本最大且唯一入组1600例、晚期非小细胞肺癌一线治疗的前瞻性、随机、双盲、全球多中心的III期研究。 OS显著延长 * Reference 1: P6 * Reference 1: P7 * * Reference 19: P2542 Reference 20: P1227 * Despite the small sample size and consequent low statistical power of this exploratory analysis, the final OS analysis for the subgroup of Asian patients in the AVAiL trial demonstrates an improvement in median OS in both Avastin arms compared with the placebo arm. The improvement in OS observed in Avastin-treated Asian patients in the AVAiL trial is greater than that observed in the overall AVAiL patient population. 1. Roche data on file. 2. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 2009. Despite the small sample size and consequent low statistical power of this exploratory analysis, the final OS analysis for the subgroup of Asian patients in the AVAiL trial demonstrates an improvement in median OS in both Avastin arms compared with the placebo arm. The improvement in OS observed in Avastin-treated Asian patients in the AVAiL trial is greater than that observed in the overall AVAiL patient population. 1. Roche data on file. 2. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 2009. Reference 19: 1525 * So there appeared a new approach: maintenance therapy to increase PFS then, overall survival instead of “watch and wait” strategy. * * 将非鳞癌作为随机的条件，在一线方案中就应用PEM，而JMEN一线方案为TAXANE,GEM RESH/990723/SH-MISC(97) * * * * * * 这张幻灯列出了已经完成的全球二线治疗的III期临床研究。 Reference 20: 1809 Reference 21: 152